Abstract
This long-term study will provide Elaprase treatment to children enrolled in this study and
will utilize data from both enrolled patients and Hunter Outcome Survey (HOS) patient
registry data to conduct the primary growth analysis to assess changes in height and weight
in patients with Mucopolysaccharidosis II (Hunter syndrome) MPS II.
